Tavapadon Lessens Motor Symptoms in Patie... - Cure Parkinson's

Cure Parkinson's

26,583 members27,900 posts

Tavapadon Lessens Motor Symptoms in Patients with Early-stage Parkinson’s, Phase 2 Trial Finds

Farooqji profile image
5 Replies

parkinsonsnewstoday.com/201...

Written by
Farooqji profile image
Farooqji
To view profiles and participate in discussions please or .
5 Replies
francis6 profile image
francis6

Encouraging, thanks for posting.

sharoncrayn profile image
sharoncrayn

IQ:

The study was terminated EARLY. So much for that drug.

Sharon

Farooqji profile image
Farooqji in reply tosharoncrayn

Preparations are underway to start phase 3 in 2020

neurologytimes.com/article/...

sharoncrayn profile image
sharoncrayn in reply toFarooqji

Obviously my mistake or the person who wrote what I read. I thought I had read it was terminated early, but obviously not so from the press release.

sharoncrayn profile image
sharoncrayn in reply toFarooqji

IQ:

This is the problem I was referring to with this drug.

So how did they obfuscate these early results to continue on with another clinical trial? A lack of efficacy in one clinical trial apparently doesn't matter.

Difficult not to be cynical about some of these trials.

"Although a previous study of tavapadon (NCT02687542) was terminated early due to lack of efficacy in moderate to advanced Parkinson’s, the “favorable profile of tavapadon in clinical studies to date” support its potential “both as a monotherapy for patients with early-stage disease and as an adjunct to levodopa for patients with late-stage disease,” said Raymond Sanchez, MD, chief medical officer at Cerevel (which was launched by Pfizer and Bain Capital in October 2018)."

Not what you're looking for?

You may also like...

Oral ANVS401 Improves Patients’ Motor Skills in Phase 2 Trial

' Once-a-day treatment with oral ANVS401 was found to significantly improve motor skills among...

Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease

Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s...

Nicotinamide Exacerbates Motor Symptoms of Parkinson’s Disease in Mice

https://parkinsonsnewstoday.com/2018/10/10/nicotinamide-exacerbates-motor-symptoms-of-parkinsons-dis
Greenday profile image

leukemia drug nilotinib could halt the progression of motor- and non-motor-related symptoms in Parkinson’s disease.

Specifically, they discovered that the 300-mg dose of nilotinib reversed these effects by...
JustJeff profile image

Diet and the gut microbiome in patients with Parkinson’s disease

https://www.nature.com/articles/s41531-024-00681-7
Farooqji profile image